1.Electrochemical fingerprint of traditional Chinese medicines based on BrO⁻₃-Ce⁴⁺-H⁺-malonic acid/tartaric acid chemical oscillating system.
Bao-Zhong DU ; Gui-Yue ZHANG ; Hua FAN ; Wei YU
China Journal of Chinese Materia Medica 2018;43(21):4288-4294
A new composite organic oscillating reaction system based on BrO₃-Ce(SO₄)₂-H₂SO₄-malonic acid/tartaric acid was proposed in this paper. On the basis of the influence of the concentration of each component on the stability and characteristic parameters of the blank system, the electrochemical fingerprints of 30 kinds of traditional Chinese medicines (TCM) were obtained. The results showed that the electrochemical fingerprint can be used for the identification of TCMs, the distinguishment of different parts and the appraisal of genuineness, which is fast, sensitive and accurate. At the same time, we explored and verified the mechanism of oscillation and the formation mechanism of TCM fingerprint.
Drugs, Chinese Herbal
;
chemistry
;
Electrochemical Techniques
;
Malonates
;
chemistry
;
Medicine, Chinese Traditional
;
Phytochemicals
;
analysis
;
Tartrates
;
chemistry
2.Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer.
Kyung Hee LEE ; Myung Soo HYUN ; Hoon Kyo KIM ; Hyung Min JIN ; Jinmo YANG ; Hong Suk SONG ; Young Rok DO ; Hun Mo RYOO ; Joo Seop CHUNG ; Dae Young ZANG ; Ho Yeong LIM ; Jong Youl JIN ; Chang Yeol YIM ; Hee Sook PARK ; Jun Suk KIM ; Chang Hak SOHN ; Soon Nam LEE
Cancer Research and Treatment 2009;41(1):12-18
PURPOSE: Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. MATERIALS AND METHODS: One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks. RESULTS: At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths. CONCLUSION: Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
Adenocarcinoma
;
Arm
;
Chemotherapy, Adjuvant
;
Cisplatin
;
Drug Therapy, Combination
;
Fluorouracil
;
Humans
;
Incidence
;
Malonates
;
Nausea
;
Neutropenia
;
Organoplatinum Compounds
;
Proteinuria
;
Stomach Neoplasms
;
Vomiting
3.Integration of A Deep Learning Classifier with A Random Forest Approach for Predicting Malonylation Sites.
Zhen CHEN ; Ningning HE ; Yu HUANG ; Wen Tao QIN ; Xuhan LIU ; Lei LI
Genomics, Proteomics & Bioinformatics 2018;16(6):451-459
As a newly-identified protein post-translational modification, malonylation is involved in a variety of biological functions. Recognizing malonylation sites in substrates represents an initial but crucial step in elucidating the molecular mechanisms underlying protein malonylation. In this study, we constructed a deep learning (DL) network classifier based on long short-term memory (LSTM) with word embedding (LSTM) for the prediction of mammalian malonylation sites. LSTM performs better than traditional classifiers developed with common pre-defined feature encodings or a DL classifier based on LSTM with a one-hot vector. The performance of LSTM is sensitive to the size of the training set, but this limitation can be overcome by integration with a traditional machine learning (ML) classifier. Accordingly, an integrated approach called LEMP was developed, which includes LSTM and the random forest classifier with a novel encoding of enhanced amino acid content. LEMP performs not only better than the individual classifiers but also superior to the currently-available malonylation predictors. Additionally, it demonstrates a promising performance with a low false positive rate, which is highly useful in the prediction application. Overall, LEMP is a useful tool for easily identifying malonylation sites with high confidence. LEMP is available at http://www.bioinfogo.org/lemp.
Amino Acid Sequence
;
genetics
;
Amino Acids
;
Animals
;
Deep Learning
;
Forecasting
;
methods
;
Lysine
;
chemistry
;
Machine Learning
;
Malonates
;
chemistry
;
Protein Processing, Post-Translational
;
genetics
4.Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer.
Young Joo MIN ; Sung Jo BANG ; Jung Woo SHIN ; Do Ha KIM ; Jae Hoo PARK ; Gyu Yeol KIM ; Byung Kyun KO ; Dae Hwa CHOI ; Hong Rae CHO
Journal of Korean Medical Science 2004;19(3):369-373
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Disease-Free Survival
;
Female
;
Fluorouracil/*administration & dosage
;
Follow-Up Studies
;
Human
;
Male
;
Malonates/*administration & dosage
;
Middle Aged
;
Organoplatinum Compounds/*administration & dosage
;
Stomach Neoplasms/*drug therapy
;
Time Factors
;
Treatment Outcome
5.Identification of Novel Compound Heterozygous Mutations in the ACADS Gene of an Asymptomatic Korean Newborn with Short Chain Acyl-CoA Dehydrogenase Deficiency by Tandem Mass Spectrometry.
Chong Kun CHEON ; Hyung Soon CHOI ; Su Yung KIM ; Han Wook YOO ; Gu Hwan KIM
Journal of Genetic Medicine 2012;9(1):42-46
Short-chain acyl-CoA dehydrogenase deficiency (SCADD; OMIM # 201470) is an autosomal recessive inborn error of mitochondrial fatty acid beta-oxidation, presenting with a variety of clinical signs and symptoms. Developmental delay, hypertonia or hypotonia, ketotic hypoglycemia, and epilepsy are most frequently reported. In general, patients diagnosed through newborn screening have shown normal growth and development in contrast to those diagnosed as a result of clinically initiated evaluations. Here, the case of an asymptomatic Korean newborn with SCADD identified by tandem mass spectrometry is reported. The patient showed an elevated concentration of butyrylcarnitine detected on newborn screening. Urinary excretion of ethylmalonic acid was elevated by urine organic acid analysis. To confirm the diagnosis of SCADD, a direct sequencing analysis of 10 coding exons and the exon-intron boundaries of the ACADS gene were performed. Genetic analysis of ACADS showed the following novel compound heterozygous missense mutations: c.277C>A (p.Leu93Ile) on exon3 and c.682G>A (p.Glu288Lys) on exon6. These results will provide further evidence of mutational heterogeneity for SCADD.
Acyl-CoA Dehydrogenase
;
Butyryl-CoA Dehydrogenase
;
Carnitine
;
Clinical Coding
;
Databases, Genetic
;
Epilepsy
;
Exons
;
Growth and Development
;
Humans
;
Hypoglycemia
;
Infant, Newborn
;
Malonates
;
Mass Screening
;
Muscle Hypotonia
;
Population Characteristics
;
Tandem Mass Spectrometry
6.Malonylcarnitine in newborns with non-syndromic cleft lip with or without cleft palate.
Kamil Konrad HOZYASZ ; Mariusz OLTARZEWSKI ; Zofia DUDKIEWICZ
International Journal of Oral Science 2010;2(3):136-141
AIMMalonyl-CoA is regarded as a key signaling molecule in mammalian cells. It is converted to acetyl-CoA, and to a lesser extent, to malonyl acid and malonylcarnitine (C3DC). Availability of carnitine has been reported to be essential for the developing fetus. The objectives of the present study were to analyze associations of malonylcarnitine, acetylcarnitine (C2), and free carnitine (CO) in subjects with orofacial clefts.
METHODOLOGYWe performed a retrospective analysis of carnitine concentration obtained from a newborn screening program carried out in our institution. Concentrations of whole blood malonylcarnitine, acetylcarnitine, and free carnitine were measured using tandem mass spectrometry. The study group consisted of 51 children with nonsyndromic cleft lip with or without cleft palate. In total, 106 healthy children without congenital anomalies served as controls. Cut-off points were established using likelihood ratio values.
RESULTSThe mean concentration of malonylcarnitine in the cleft group was lower than that of the control group, 0.048 micromol x L(-1) vs. 0.058 micromol x L(-1), respectively (P = 0.009). In patients with orofacial cleft, low malonylcarnitine levels (< or = 0.047 micromol x L(-1)) were 1.7 times more predominant than in healthy individuals (P = -0.03). The mean concentration of acetylcarnitine was also lower in affected newborns in comparison to controls, 33.8 micromol x L(-1) vs. 37.8 micromol x L(-1), respectively (P = 0.026). After analysis of acetylcarnitine and free carnitine concentrations, the likelihood ratio test did not indicate valuable cut-offpoints.
CONCLUSIONThe study provides initial data indicating a potential association between decreased malonylcarnitine and abnormal palatogenesis.
Acetylcarnitine ; blood ; Carnitine ; blood ; Chromatography, Liquid ; Cleft Lip ; blood ; Cleft Palate ; blood ; Female ; Humans ; Infant, Newborn ; blood ; Likelihood Functions ; Male ; Malonates ; blood ; Malonyl Coenzyme A ; blood ; Neonatal Screening ; Retrospective Studies ; Tandem Mass Spectrometry
7.Design, synthesis and evaluation of malonic acid-based PTP1B inhibitors.
Xin DU ; Shu-En ZHANG ; Jun-Zheng LIU ; Fei-Lin NIE ; Fei YE ; Jin-Ying TIAN ; Zhi-Yan XIAO
Acta Pharmaceutica Sinica 2012;47(3):367-373
Protein tyrosine phosphatase (PTP) 1B is a potential target for the treatment of diabetes and obesity. Phosphotyrosine (pTyr) is the substrate for PTP1B dephosphorylation. Malonic acid moiety was used herein as a mimic of the phosphate group in pTyr, and novel malonic acid derivatives 1-7 were designed, synthesized and evaluated as PTP1B inhibitors. Results from enzymatic assays indicated that compounds 3 and 4 exhibited potent inhibition against human recombinant PTP1B with IC50 values of 7.66 and 1.88 micromol x L(-1), respectively.
Drug Design
;
Enzyme Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
Humans
;
Inhibitory Concentration 50
;
Malonates
;
chemical synthesis
;
chemistry
;
pharmacology
;
Molecular Structure
;
Protein Tyrosine Phosphatase, Non-Receptor Type 1
;
antagonists & inhibitors
;
metabolism
;
Structure-Activity Relationship
8.Crystal structures and biochemical studies of human lysophosphatidic acid phosphatase type 6.
Jun LI ; Yu DONG ; Xingru LÜ ; Lu WANG ; Wei PENG ; Xuejun C ZHANG ; Zihe RAO
Protein & Cell 2013;4(7):548-561
Lysophosphatidic acid (LPA) is an important bioactive phospholipid involved in cell signaling through Gprotein-coupled receptors pathways. It is also involved in balancing the lipid composition inside the cell, and modulates the function of lipid rafts as an intermediate in phospholipid metabolism. Because of its involvement in these important processes, LPA degradation needs to be regulated as precisely as its production. Lysophosphatidic acid phosphatase type 6 (ACP6) is an LPA-specific acid phosphatase that hydrolyzes LPA to monoacylglycerol (MAG) and phosphate. Here, we report three crystal structures of human ACP6 in complex with malonate, L-(+)-tartrate and tris, respectively. Our analyses revealed that ACP6 possesses a highly conserved Rossmann-foldlike body domain as well as a less conserved cap domain. The vast hydrophobic substrate-binding pocket, which is located between those two domains, is suitable for accommodating LPA, and its shape is different from that of other histidine acid phosphatases, a fact that is consistent with the observed difference in substrate preferences. Our analysis of the binding of three molecules in the active site reveals the involvement of six conserved and crucial residues in binding of the LPA phosphate group and its catalysis. The structure also indicates a water-supplying channel for substrate hydrolysis. Our structural data are consistent with the fact that the enzyme is active as a monomer. In combination with additional mutagenesis and enzyme activity studies, our structural data provide important insights into substrate recognition and the mechanism for catalytic activity of ACP6.
Amino Acid Sequence
;
Catalytic Domain
;
Crystallography, X-Ray
;
Humans
;
Malonates
;
metabolism
;
Models, Molecular
;
Molecular Sequence Data
;
Nitrophenols
;
metabolism
;
Organophosphorus Compounds
;
metabolism
;
Phosphoric Monoester Hydrolases
;
chemistry
;
classification
;
metabolism
;
Tartrates
;
metabolism
;
Water
;
metabolism
9.Plasma metabonomics study of ischemic cerebral apoplexy rats treated with Tongsaimai pellets.
Jiayu TU ; Jiye A ; Guangji WANG ; Hongmei WEN ; Aiyun WANG ; Liuqing DI ; Bei CAO ; Linsheng LIU
China Journal of Chinese Materia Medica 2012;37(7):1028-1033
OBJECTIVETo observe abnormal metabolic changes caused by ischemic cerebral apoplexy and the regulating action of Tongsaimai pellets on abnormal metabolism by analyzing the change of small molecules in plasma of ischemic cerebral apoplexy rat. To find the potential biomarkers, and to explore metabolic mechanisms of Tongsaimai pellets.
METHODRat models of middle cerebral artery occlusion was established with electric coagulation, and rats were divided into 4 groups, model group, sham-operation group, Tongsaimai pellets group and positive control group. Tongsaimai pellets and positive control group were orally administrated by 13.2 g x kg(-1) x d(-1) of crude drugs and 32 mg x kg(-1) x d(-1) of Nimodipine respectively, m odel and sham-operation group by equal volume of distilled water for a week. Plasma of model and sham-operation group were collected, and plasma of Tongsaimai pellets and positive control group were collected on the 1st, 3rd , 7th day after administration. Endogenous metabolites of four groups were determined with GC-MS. Partial least squares discriminant analysis (PLS-DA) was applied to analyze multivariate data and set up model, and T-test was used in significant statistical analysis.
RESULTCompared with sham-operation group rats, pyruvic acid, taurine and hydroxyproline obviously increased in model group rats, while lactic acid, glyceric acid, aminomalonic acid, fructose, tryptophan and leucine significantly decreased, so these metabolites were potential metabolic biomarkers. These endogenous metabolites except taurine got restoration in Tongsaimai group rats.
CONCLUSIONAbnormal metabolite level in plasma can be certainly recovered by Tongsaimai pellets, and the treatment of Tongsaimai pellets can be connected with the regulation of related metabolic pathways.
Animals ; Brain Ischemia ; blood ; drug therapy ; Drugs, Chinese Herbal ; therapeutic use ; Fructose ; blood ; Glyceric Acids ; blood ; Hydroxyproline ; blood ; Lactic Acid ; blood ; Leucine ; blood ; Male ; Malonates ; blood ; Metabolomics ; methods ; Pyruvic Acid ; blood ; Rats ; Rats, Sprague-Dawley ; Stroke ; blood ; drug therapy ; Taurine ; blood ; Tryptophan ; blood
10.Report of a case with methylmalonic acidemia.
Hong-hua LIN ; Cheng WU ; Yang DONG
Chinese Journal of Pediatrics 2008;46(7):557-558